S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

NVS Novartis AG

103.13

2.43 (2.41%)

May 31 2024 - Closed

Delayed by 15 minutes

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

0001370368-24-000004.txt

Novartis (NYSE:NVS)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Novartis Charts.

Novartis (NYSE:NVS)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Novartis Charts.

Novartis AG News

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Saturday 25 May 2024 (1 week ago) • PR Newswire (US)

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Saturday 25 May 2024 (1 week ago) • PR Newswire (US)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Friday 24 May 2024 (1 week ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 22 May 2024 (1 week ago) • Edgar (US Regulatory)

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
Tuesday 7 May 2024 (4 weeks ago) • GlobeNewswire Inc.

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
Tuesday 23 April 2024 (1 month ago) • IH Market News

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Monday 15 April 2024 (2 months ago) • PR Newswire (US)

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Thursday 11 April 2024 (2 months ago) • GlobeNewswire Inc.

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Wednesday 10 April 2024 (2 months ago) • IH Market News

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Saturday 6 April 2024 (2 months ago) • PR Newswire (US)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Thursday 15 February 2024 (4 months ago) • Edgar (US Regulatory)

Form SC TO-C - Written communication relating to an issuer or third party
Tuesday 6 February 2024 (4 months ago) • Edgar (US Regulatory)

More Novartis AG News Articles

FOXO Technologies

TPT Global Tech (PK)

RespireRx Pharmaceuticals (PK)

GNCC Capital (CE)

Impact Fusion (PK)

1812 Brewing (PK)

Code Green Apparel (PK)

Trump Media and Technology

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions